DiaMedica Therapeutics Inc. - Common Stock (DMAC)

Stroke trial hit its interim milestone as cash runs into late 2027.

DiaMedica Therapeutics (NASDAQ:DMAC) expects a key interim analysis of its acute ischemic stroke trial in the first quarter of 2027, after reaching the required enrollment threshold in October, executives said on the company’s third-quarter earnings call. The company also completed enrollment in th

ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete.

DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the company reported a cash runway it expects to extend through 2027. President and Chief Executive Offi

DiaMedica (DMAC) Q4 2025 Earnings Transcript

DiaMedica (DMAC) Q1 2026 Earnings Transcript

DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.

DiaMedica reports Q3 2025 results, advancing DM199 for stroke and preeclampsia. The company has a cash runway into H2 2027 to fund clinical trials.

DiaMedica Therapeutics reports Q2 2025 results with a narrower-than-expected loss, positive clinical updates, and strong cash position. Stock surges 19% post-earnings.